{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:06:37Z","timestamp":1794330397595,"version":"4.9.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ijantimicag.2017.08.010","type":"journal-article","created":{"date-parts":[[2017,8,9]],"date-time":"2017-08-09T14:15:23Z","timestamp":1502288123000},"page":"617-621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"title":["Antifungal resistance in mucorales"],"prefix":"10.1016","volume":"50","author":[{"given":"E.","family":"Dannaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0010","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0015","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1128\/CMR.13.2.236-301.2000","article-title":"Zygomycetes in human disease","volume":"13","author":"Ribes","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.idc.2015.10.011","article-title":"Mucormycoses","volume":"30","author":"Farmakiotis","year":"2016","journal-title":"Infect Dis Clin North Am"},{"issue":"Suppl. 6","key":"10.1016\/j.ijantimicag.2017.08.010_bib0025","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/1469-0691.12466","article-title":"Why is mucormycosis more difficult to cure than more common mycoses?","volume":"20","author":"Katragkou","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2017.08.010_bib0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0035","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case\u2013control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0040","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1128\/JCM.01685-08","article-title":"Sequence-based identification of Aspergillus, Fusarium, and Mucorales species in the clinical mycology laboratory: where are we and where should we go from here?","volume":"47","author":"Balajee","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0045","series-title":"Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard\u2013second edition","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0050","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1469-0691.2008.02086.x","article-title":"EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds","volume":"14","author":"Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing","year":"2008","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 5","key":"10.1016\/j.ijantimicag.2017.08.010_bib0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1469-0691.2009.02984.x","article-title":"In vitro activity of antifungals against zygomycetes","volume":"15","author":"Alastruey-Izquierdo","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3767\/003158513X665070","article-title":"DNA barcoding in Mucorales: an inventory of biodiversity","volume":"30","author":"Walther","year":"2013","journal-title":"Persoonia"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2017.08.010_bib0065","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/cir880","article-title":"A global analysis of mucormycosis in France: the RetroZygo study (2005\u20132007)","volume":"54","author":"Lanternier","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0070","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/AAC.01919-15","article-title":"In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order","volume":"59","author":"Arendrup","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/dkg020","article-title":"In vitro susceptibilities of zygomycetes to conventional and new antifungals","volume":"51","author":"Dannaoui","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0080","doi-asserted-by":"crossref","first-page":"7882","DOI":"10.1128\/AAC.02107-15","article-title":"Comparison of the EUCAST and CLSI broth microdilution methods for testing isavuconazole, posaconazole, and amphotericin B against molecularly identified Mucorales species","volume":"59","author":"Chowdhary","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0085","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1128\/AAC.00004-15","article-title":"Etest cannot be recommended for in vitro susceptibility testing of Mucorales","volume":"59","author":"Caramalho","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2017.08.010_bib0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/myc.12234","article-title":"Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India","volume":"57","author":"Chowdhary","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0095","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1093\/jac\/dks137","article-title":"In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs","volume":"67","author":"Drogari-Apiranthitou","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0100","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1128\/JCM.00925-15","article-title":"Comparing Etest and broth microdilution for antifungal susceptibility testing of the most-relevant pathogenic molds","volume":"53","author":"Lamoth","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0105","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1128\/AAC.47.11.3647-3650.2003","article-title":"Activity of posaconazole in treatment of experimental disseminated zygomycosis","volume":"47","author":"Dannaoui","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0110","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1128\/AAC.46.6.1953-1959.2002","article-title":"Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis","volume":"46","author":"Dannaoui","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0115","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dkw433","article-title":"Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis","volume":"72","author":"Gebremariam","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0120","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1128\/AAC.49.2.721-727.2005","article-title":"Caspofungin inhibits Rhizopus oryzae 1,3-\u03b2-d-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis","volume":"49","author":"Ibrahim","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0125","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1172\/JCI32338","article-title":"The iron chelator deferasirox protects mice from mucormycosis through iron starvation","volume":"117","author":"Ibrahim","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0130","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1128\/AAC.01458-07","article-title":"Combination echinocandin\u2013polyene treatment of murine mucormycosis","volume":"52","author":"Ibrahim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0135","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1128\/AAC.01577-10","article-title":"Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins","volume":"55","author":"Ibrahim","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0140","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1128\/AAC.01124-08","article-title":"Posaconazole mono- or combination therapy for treatment of murine zygomycosis","volume":"53","author":"Ibrahim","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0145","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1128\/AAC.02301-13","article-title":"Isavuconazole therapy protects immunosuppressed mice from mucormycosis","volume":"58","author":"Luo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0150","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1128\/AAC.00313-13","article-title":"Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis","volume":"57","author":"Luo","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0155","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1128\/AAC.01026-09","article-title":"Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection","volume":"53","author":"Rodriguez","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0160","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1128\/AAC.01463-09","article-title":"Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice","volume":"54","author":"Rodriguez","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0165","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1128\/AAC.00628-08","article-title":"Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae","volume":"52","author":"Rodriguez","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0170","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1128\/AAC.05956-11","article-title":"In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole","volume":"56","author":"Salas","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0175","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.49.2.830-832.2005","article-title":"Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice","volume":"49","author":"Spellberg","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0180","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1093\/jac\/dkq276","article-title":"In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility","volume":"65","author":"Spreghini","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0185","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1128\/AAC.04435-14","article-title":"Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales","volume":"59","author":"Espinel-Ingroff","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0190","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1128\/AAC.04424-14","article-title":"Susceptibility profiles of amphotericin B and posaconazole against clinically relevant Mucorales species under hypoxic conditions","volume":"59","author":"Maurer","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/JCM.06133-11","article-title":"Antifungal susceptibility and phylogeny of opportunistic members of the order Mucorales","volume":"50","author":"Vitale","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0200","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1128\/AAC.00452-07","article-title":"In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents","volume":"51","author":"Almyroudis","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0205","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/AAC.46.5.1581-1582.2002","article-title":"In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes","volume":"46","author":"Sun","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0210","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/423274","article-title":"Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole","volume":"39","author":"Imhof","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0215","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1086\/597615","article-title":"Increased virulence of zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis","volume":"199","author":"Lamaris","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0220","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1128\/AAC.01467-08","article-title":"Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers","volume":"53","author":"Alastruey-Izquierdo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0225","series-title":"New insights in fungal pathogenicity","first-page":"159","article-title":"The zygomycetes","author":"Dannaoui","year":"2007"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2017.08.010_bib0230","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1093\/cid\/cir885","article-title":"Combination therapy for mucormycosis: why, what, and how?","volume":"54","author":"Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0235","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1128\/AAC.02612-12","article-title":"Drug combinations against Mucor irregularis in vitro","volume":"57","author":"Zhang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0240","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkr375","article-title":"The Deferasirox\u2013AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial","volume":"67","author":"Spellberg","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0245","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene\u2013caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.08.010_bib0250","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cmi.2016.03.029","article-title":"Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis","volume":"22","author":"Kyvernitakis","year":"2016","journal-title":"Clin Microbiol Infect"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917303023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917303023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T13:01:08Z","timestamp":1535461268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917303023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0924857917303023"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.08.010","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antifungal resistance in mucorales","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}